Relay Therapeutics Secures Breakthrough Designation for Zovegalisib in Breast Cancer
Event summary
- FDA granted Breakthrough Therapy designation to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer.
- Phase 3 ReDiscover-2 trial for zovegalisib in 2L breast cancer is ongoing.
- Phase 1/2 trial of RLY-8161, a NRAS-selective molecule, initiated in NRAS-mutant solid tumors.
- Company reported $642 million in cash, cash equivalents, and investments as of Q1 2026.
The big picture
Relay Therapeutics is advancing its precision medicine pipeline with zovegalisib, targeting a significant portion of HR+/HER2- breast cancer patients with PI3Kα mutations. The FDA's Breakthrough Therapy designation underscores the potential of zovegalisib, while the initiation of the RLY-8161 trial expands the company's reach into NRAS-mutant solid tumors. The biotech sector continues to focus on mutant-selective inhibitors, and Relay Therapeutics' Dynamo® platform positions it as a key player in this evolving landscape.
What we're watching
- Regulatory Momentum
- Whether the FDA Breakthrough Therapy designation will accelerate zovegalisib's path to market.
- Clinical Execution
- The pace at which Relay Therapeutics can initiate and complete its Phase 3 frontline breast cancer trial in early 2027.
- Financial Runway
- How Relay Therapeutics will manage its cash position to fund operations into 2029.
Related topics